WW Team:

As the week draws to a close, I want to take a moment to address some of the breathless media coverage that I'm sure many of you have seen. These headlines are often just speculation.

First, we believe the recent stock price moves do not reflect the strength of our performance, outlook or the near term trade-offs we’re making for our future growth. As we shared in our recent earnings report, we have returned the company to a positive trajectory. In fact, we are on track to beat our Q1 guidance for Clinic subscribers.

Additionally, we have strong liquidity and are not in a cash crunch. We have very attractive, long-term debt agreements, with no maturities due until 2028 and 2029, which gives us ample time to deliver on our transformation and growth strategy.

Turning around and totally transforming a business is not for the faint of heart! As we stay focused on delivering for our members, the stock price will take care of itself. The work you are doing matters and is setting us up for long-term success.

Along with our Board and leadership team, I have great confidence in the future of WeightWatchers. We’re executing on a specific plan to grow subscription revenue, subscribers, gross margin and operating income this year. Our business is healthy, and we are well-positioned for the future as we continue our transformation.

We’ve repositioned this company to grow with a clear differentiator – offering a full spectrum of weight care across behavioral and clinical solutions. I’m more committed than ever to our mission as the global leader in weight health by delivering the support, services and treatments that we know so many in this world need today.

You can also feel good that we’re making values-based decisions that prioritize member safety, even as many in our space are peddling compounded solutions for a quick buck in this supply-constrained environment. I am proud that we continue to grow our clinic business with integrity. With a wide formulary and holistic weight loss care, our members are only prescribed FDA-approved medications alongside our stigma-free and specialized care.

Again, I know clickbait stories and their predictable, albeit temporary, market impact don’t feel great. But take pride, because we will prove the naysayers wrong. Stay focused, stay confident, stay strong and stay the course. We’re on the right track.

🌈 Sima